There are 327 resources available
97O - PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels
Presenter: Thomas Hatschek
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
138O - CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses
Presenter: Guy Jerusalem
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
137O - Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)
Presenter: Giuseppe Curigliano
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
127O - Tumour mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
Presenter: Thomas Karn
Session: Proffered papers 3 - Best abstracts
Resources:
Abstract
Slides
Webcast
128O - PDL1/CD274 gain/amplification as a predictive marker of checkpoint blockade inhibitor efficacy in metastatic breast cancer: Exploratory analysis of the SAFIR02-IMMUNO randomized phase II trial
Presenter: Thomas Bachelot
Session: Proffered papers 3 - Best abstracts
Resources:
Abstract
Slides
Webcast
4P - Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)+/HER2+ breast cancer (BC)
Presenter: Tomas Pascual
Session: ePoster
Resources:
Abstract
5P - Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i)
Presenter: Olga Martinez Saez
Session: ePoster
Resources:
Abstract
6P - Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)
Presenter: Francesca Galardi
Session: ePoster
Resources:
Abstract
7P - Prognostic value of the immune infiltration score in early breast cancer patients receiving dual HER2 blockade with trastuzumab and pertuzumab: An exploratory analysis of a randomized clinical trial
Presenter: Guoxing Wan
Session: ePoster
Resources:
Abstract
8P - Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)
Presenter: Gaia Griguolo
Session: ePoster
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.